Impact of nitazoxanide on sustained virologic response in Egyptian patients with chronic hepatitis C genotype 4: a double-blind placebo-controlled trial
Background Nitazoxanide, approved for the treatment of Cryptosporidium parvum and
Giardia lamblia, was found to inhibit hepatitis C virus replication. Aim The aim of this study
was to assess the impact of nitazoxanide as an add-on therapy to pegylated interferon α-2a
and ribavirin on sustained virologic response (SVR) in patients with chronic hepatitis C.
Giardia lamblia, was found to inhibit hepatitis C virus replication. Aim The aim of this study
was to assess the impact of nitazoxanide as an add-on therapy to pegylated interferon α-2a
and ribavirin on sustained virologic response (SVR) in patients with chronic hepatitis C.